Unknown

Dataset Information

0

CD19 CAR T cell product and disease attributes predict leukemia remission durability.


ABSTRACT: BACKGROUND:Chimeric antigen receptor (CAR) T cells can induce remission in highly refractory leukemia and lymphoma subjects, yet the parameters for achieving sustained relapse-free survival are not fully delineated. METHODS:We analyzed 43 pediatric and young adult subjects participating in a Phase I trial of defined composition CD19CAR T cells (NCT02028455). CAR T cell phenotype, function and expansion, as well as starting material T cell repertoire, were analyzed in relation to therapeutic outcome (defined as achieving complete remission within 63 days) and duration of leukemia free survival and B cell aplasia. RESULTS:These analyses reveal that initial therapeutic failures (n = 5) were associated with attenuated CAR T cell expansion and/or rapid attrition of functional CAR effector cells following adoptive transfer. The CAR T products were similar in phenotype and function when compared to products resulting in sustained remissions. However, the initial apheresed peripheral blood T cells could be distinguished by an increased frequency of LAG-3+/TNF-?low CD8 T cells and, following adoptive transfer, the rapid expression of exhaustion markers. For the 38 subjects who achieved an initial sustained MRD-neg remission, remission durability correlated with therapeutic products having increased frequencies of TNF-?-secreting CAR CD8+ T cells, and was dependent on a sufficiently high CD19+ antigen load at time of infusion to trigger CAR T cell proliferation. CONCLUSION:These parameters have the potential to prospectively identify patients at risk for therapeutic failure and support the development of approaches to boost CAR T cell activation and proliferation in patients with low levels of CD19 antigen. TRIAL REGISTRATION:ClinicalTrials.gov NCT02028455. FUNDING:Partial funding for this study was provided by Stand Up to Cancer & St. Baldrick's Pediatric Dream Team Translational Research Grant (SU2C-AACR-DT1113), RO1 CA136551-05, Alex Lemonade Stand Phase I/II Infrastructure Grant, Conquer Cancer Foundation Career Development Award, Washington State Life Sciences Discovery Fund, Ben Towne Foundation, William Lawrence & Blanche Hughes Foundation, and Juno Therapeutics, Inc., a Celgene Company.

SUBMITTER: Finney OC 

PROVIDER: S-EPMC6486329 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

CD19 CAR T cell product and disease attributes predict leukemia remission durability.

Finney Olivia C OC   Brakke Hannah M HM   Rawlings-Rhea Stephanie S   Hicks Roxana R   Doolittle Danielle D   Lopez Marisa M   Futrell Robert B RB   Orentas Rimas J RJ   Li Daniel D   Gardner Rebecca A RA   Jensen Michael C MC  

The Journal of clinical investigation 20190312 5


<h4>Background</h4>Chimeric antigen receptor (CAR) T cells can induce remission in highly refractory leukemia and lymphoma subjects, yet the parameters for achieving sustained relapse-free survival are not fully delineated.<h4>Methods</h4>We analyzed 43 pediatric and young adult subjects participating in a Phase I trial of defined composition CD19CAR T cells (NCT02028455). CAR T cell phenotype, function and expansion, as well as starting material T cell repertoire, were analyzed in relation to t  ...[more]

Similar Datasets

| S-EPMC8571234 | biostudies-literature
| S-EPMC3621858 | biostudies-literature
| S-EPMC6695558 | biostudies-literature
| S-EPMC5482103 | biostudies-literature
| S-EPMC7877347 | biostudies-literature
| S-EPMC8428364 | biostudies-literature
| S-EPMC5774642 | biostudies-literature
| S-EPMC6354733 | biostudies-literature
| S-EPMC6637939 | biostudies-literature
| S-EPMC7519582 | biostudies-literature